Drug Type Bispecific antibody  | 
Synonyms Anti-CD40/B7H3 Bispecific antibody(Lyvgen Biopharma Co., Ltd)  | 
Target  | 
Action modulators, agonists  | 
Mechanism CD276 modulators(CD276 antigen modulators), CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists)  | 
Therapeutic Areas  | 
Active Indication-  | 
Inactive Indication  | 
Originator Organization  | 
Active Organization-  | 
Inactive Organization  | 
License Organization-  | 
Drug Highest PhasePendingDiscovery  | 
First Approval Date-  | 
Regulation-  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Discovery | United States   | 23 Oct 2020 | 






